Will a thrombosis medication help with Alzheimer's disease?
Scientists have found that a heart drug helps treat Alzheimer's disease
A new study from the University of Örebro suggests that the heart drug acts on the formation of plaques in the vessels of the brain.
So far, the study has been conducted on laboratory mice and may help bring the drug against Alzheimer's disease closer.
Swedish scientists, together with German and Italian colleagues, have discovered that a previously unknown mechanism is the cause of a rapid increase in the number of plaques in blood vessels, including in the brain.
In tests involving mice, scientists tried to establish whether it was possible to reduce the formation of plaques by using a specific drug used to treat heart diseases.
However, it is too early to draw any serious conclusions from the experimental experiments, although further research will follow this path, said Magnus Grenegaard, a professor from the University of Örebro, who is working on the study with the team (in a press release Örebro University Will heart medicine help treat Alzheimer's disease? – VM).
Observations have shown how the beta-amyloid protein is attracted to platelets, sticking to their surface, which initiates a rapid chain reaction. As a result, there is a high rate of plaque buildup.
This plaque formation causes the rapid death of nerve cells, causing symptoms indicative of Alzheimer's disease, including memory problems, Magnus Grenegaard believes.
This work is a fundamental study at the cellular and molecular levels, pointing to a path that was previously unknown. It turned out that blood cells are of great importance in the formation of plaques on the walls of blood vessels in people with Alzheimer's disease.
Therefore, a widely used drug for the treatment of the heart was tested, used to prevent and minimize the rate of blood clots, which significantly reduces the risk of heart attack. This work showed that the plaques decreased after the use of the heart medication.
In the press release, the name of the drug is delicately hushed up, but in the article by Donner et al. Platelets contribute to amyloid-β aggregation in cerebral vessels through integrin aIIbß3–induced outside-in signaling and clusterin release, published in the journal Science Signaling, it is written that this is Clopidogrel (Clopidogrel) – VM.
As expected, the medicine slowed down the process. This turned out to be true not only for blood vessels in general, but also for those located in the brain tissue itself. To make a final conclusion, further research is required. However, a previously unknown approach has already been defined.
To date, this disease is a terrible verdict, as it is characterized by total damage to brain tissue. Early symptoms are a decrease in memory and the ability to perform everyday tasks, but, ultimately, the entire brain suffers, which makes a person unable to lead a normal life.
More than 100,000 Swedes have been diagnosed with Alzheimer's disease, which brings great suffering not only to the patient, but also to his family. So the new effective drug will be met positively, Magnus Grenegaard believes.
Portal "Eternal youth" http://vechnayamolodost.ru
03.06.2016